Compare BNR & DH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNR | DH |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.5M | 89.9M |
| IPO Year | 2019 | 2021 |
| Metric | BNR | DH |
|---|---|---|
| Price | $9.36 | $0.86 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.08 |
| AVG Volume (30 Days) | 20.8K | ★ 571.4K |
| Earning Date | 06-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,521,000.00 |
| Revenue This Year | $111.65 | N/A |
| Revenue Next Year | N/A | $0.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.51 | $0.62 |
| 52 Week High | $41.72 | $4.70 |
| Indicator | BNR | DH |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 54.48 |
| Support Level | $8.05 | $0.80 |
| Resistance Level | $13.89 | $1.04 |
| Average True Range (ATR) | 0.85 | 0.08 |
| MACD | 0.55 | 0.01 |
| Stochastic Oscillator | 90.32 | 84.82 |
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.